Omalizumab: A Comprehensive Review of its Mechanism, Indications, Pharmacokinetics, Safety, and Economic Impact

Many thanks to our sponsor Esdebe who helped us prepare this research report.

Abstract

Omalizumab, a recombinant humanized monoclonal antibody targeting immunoglobulin E (IgE), has revolutionized the management of several allergic and inflammatory conditions. Since its initial approval in 2003 for severe allergic asthma, its therapeutic utility has expanded to include chronic spontaneous urticaria (CSU), chronic rhinosinusitis with nasal polyps (CRSwNP), and IgE-mediated food allergy. This comprehensive report delves into the precise mechanism of action of omalizumab, highlighting its unique anti-IgE properties and their downstream effects on immune cells. We provide a detailed overview of its pharmacokinetics and pharmacodynamics, crucial for understanding its dosing regimens and sustained clinical effects. Furthermore, the report presents an in-depth analysis of its efficacy and safety profile across its approved indications, with a specific focus on the pediatric population in CSU. Long-term safety data from real-world studies are critically examined, alongside potential drug interactions. Finally, a cost-benefit analysis is discussed, contextualizing omalizumab’s role within modern medicine and evaluating its economic implications compared to conventional therapies. This review aims to furnish experts in the field with a holistic understanding of omalizumab’s current standing and future prospects in the therapeutic landscape.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

1. Introduction

Allergic diseases and inflammatory conditions driven by aberrant immune responses represent a significant global health burden, impacting millions and often leading to diminished quality of life and considerable healthcare costs. Immunoglobulin E (IgE) plays a pivotal role in the pathophysiology of a wide array of these disorders, mediating immediate hypersensitivity reactions and contributing to chronic inflammation. The recognition of IgE’s central involvement spurred the development of targeted therapies, among which omalizumab stands out as a pioneering biological agent. Omalizumab, marketed under the trade name Xolair, is a recombinant DNA-derived humanized IgG1 monoclonal antibody designed to selectively bind to free human IgE.

First approved by the U.S. Food and Drug Administration (FDA) in 2003 for the treatment of moderate-to-severe persistent allergic asthma, omalizumab marked a paradigm shift in the management of severe respiratory allergic diseases. Its utility has since expanded, gaining approval for chronic spontaneous urticaria (CSU) in 2014, chronic rhinosinusitis with nasal polyps (CRSwNP), and more recently, IgE-mediated food allergy. This broadened applicability underscores its versatility and the effectiveness of IgE neutralization as a therapeutic strategy. While initially recognized for its role in allergic asthma, the increasing evidence of its efficacy and safety in diverse conditions, particularly in chronic urticaria across various age groups, necessitates a comprehensive review. This report aims to consolidate current knowledge regarding omalizumab’s multifaceted profile, from its intricate molecular mechanism to its real-world clinical implications and economic considerations.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

2. Mechanism of Action

Omalizumab’s therapeutic efficacy stems from its highly specific and targeted interaction with immunoglobulin E. As a humanized IgG1 monoclonal antibody, omalizumab is engineered to bind to the Cε3 domain of the IgE heavy chain, the same epitope responsible for IgE binding to its high-affinity receptor, FcεRI, found predominantly on mast cells and basophils. By competitively binding to free IgE in the circulation and interstitial fluids, omalizumab effectively neutralizes IgE, preventing its attachment to FcεRI on effector cells.

The primary consequence of this IgE sequestration is a significant reduction in circulating free IgE levels in a dose-dependent manner. This reduction, in turn, leads to a marked downregulation of FcεRI expression on the surface of mast cells, basophils, and antigen-presenting dendritic cells. The decreased number of IgE receptors renders these cells less responsive to IgE-mediated activation, thereby inhibiting the downstream cascade of inflammatory mediator release, such as histamine, leukotrienes, and cytokines, which are central to allergic and inflammatory reactions.

While the mechanism in allergic diseases like asthma is largely understood through this direct IgE neutralization and FcεRI downregulation, its precise mechanism in chronic spontaneous urticaria (CSU) is considered more complex and not entirely elucidated. CSU is not a classical allergen-driven disease, and a fixed dose of omalizumab is approved for this condition, irrespective of serum IgE levels or body weight, unlike asthma. Emerging theories suggest that in CSU, omalizumab may exert its effects by reducing mast cell releasability, reversing basopenia (low basophil counts), improving basophil IgE receptor function, and potentially by reducing the activity of autoantibodies (IgG and IgE) against FcεRI or IgE itself, which are implicated in a subset of CSU patients. The ability of omalizumab to stabilize mast cells, rendering them less prone to degranulation, is also considered a fundamental mechanism across various IgE-mediated and non-allergic mast cell-driven conditions.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

3. Approved Indications and Efficacy

Omalizumab’s clinical utility extends across several severe allergic and inflammatory conditions, demonstrating significant efficacy in improving patient outcomes. Its regulatory approvals reflect its broad-spectrum anti-IgE effects.

3.1. Severe Allergic Asthma

Omalizumab was first approved for the treatment of moderate-to-severe persistent allergic asthma in patients aged 6 years and older who have a positive skin test or in vitro reactivity to a perennial aeroallergen and whose symptoms are inadequately controlled with inhaled corticosteroids. In this indication, omalizumab has consistently shown a reduction in the incidence of asthma exacerbations, a key outcome for patients with severe disease.

Clinical trials and real-world studies have demonstrated significant improvements in lung function (e.g., FEV1, mPEF), asthma control (e.g., ACT, ACQ scores), and quality of life (e.g., AQLQ scores). It also exhibits a notable oral corticosteroid (OCS)-sparing effect, allowing many patients to reduce or discontinue OCS, thereby mitigating the severe systemic side effects associated with long-term corticosteroid use. The efficacy appears to be sustained over long-term treatment periods, with benefits observed up to 8-11 years in real-world settings. A meta-analysis in pediatric asthma patients specifically concluded that omalizumab significantly reduces exacerbation rates and improves overall treatment effectiveness.

3.2. Chronic Spontaneous Urticaria (CSU)

For chronic spontaneous urticaria (CSU), omalizumab is approved for adults and adolescents 12 years of age and older who remain symptomatic despite H1-antihistamine treatment. CSU significantly impairs quality of life, and for those refractory to conventional antihistamine therapy, omalizumab offers a crucial therapeutic option.

In this population, omalizumab has shown remarkable efficacy in reducing the severity and frequency of hives (urticaria) and angioedema, leading to significant improvements in Urticaria Activity Score (UAS7) and quality of life (DLQI). Response rates are high, with studies reporting pooled response rates of 88.0% and complete response rates of 51.0% in pediatric CSU. In adolescents, efficacy and safety profiles are also favorable, with nearly 90% achieving a complete response in some cohorts. The effect is generally rapid, with improvements often observed within weeks of initiation. For pediatric patients under 12, while off-label for CSU, emerging data from systematic reviews and real-world studies suggest high efficacy and an acceptable safety profile, though data remain scarcer than for older age groups. The ability of omalizumab to significantly reduce disease activity and improve quality of life in pediatric CSU patients, as demonstrated by a 75.3% reduction in UAS7 scores at 52 weeks in one study, highlights its transformative impact in a population with limited conventional options.

3.3. Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

Omalizumab is also indicated as an add-on maintenance treatment for adults (18 years and older) with chronic rhinosinusitis with nasal polyps (CRSwNP) who have an inadequate response to nasal corticosteroids. CRSwNP is often associated with Type 2 inflammation and high IgE levels, making anti-IgE therapy a logical approach.

Clinical trials (POLYP 1 and POLYP 2) have demonstrated that omalizumab significantly improves objective measures such as Nasal Polyp Score (NPS) and Nasal Congestion Score (NCS), as well as patient-reported outcomes like the Sino-Nasal Outcome Test-22 (SNOT-22) and sense of smell (UPSIT). Furthermore, it reduces the need for systemic corticosteroids and revision surgeries, addressing significant unmet needs in this patient population. Long-term extension studies suggest the durability of these responses, although discontinuation can lead to gradual symptom worsening.

3.4. IgE-Mediated Food Allergy

The most recent approval for omalizumab is for the reduction of allergic reactions (Type I), including anaphylaxis, that may occur with accidental exposure to one or more foods in patients aged one year and older with IgE-mediated food allergy. It is important to note that omalizumab is to be used in conjunction with food allergen avoidance and is not indicated for the emergency treatment of acute allergic reactions. This indication acknowledges the drug’s potential to raise the threshold of reactivity to allergens, thereby offering a crucial safety net for individuals at risk of accidental exposure. In pediatric patients, omalizumab has shown superiority in desensitization compared to placebo in food allergy.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

4. Pharmacokinetics and Pharmacodynamics

The pharmacokinetic (PK) and pharmacodynamic (PD) profiles of omalizumab are crucial for understanding its sustained therapeutic effects and guiding appropriate dosing.

4.1. Pharmacokinetics

Omalizumab is administered subcutaneously, typically every 2 to 4 weeks, with dosing regimens varying based on body weight and baseline serum IgE levels for asthma and food allergy indications. For CSU, a fixed dose is used regardless of body weight or IgE. The average absolute bioavailability following subcutaneous administration is approximately 62%. Absorption is slow, with peak serum concentrations generally occurring 7 to 8 days after administration.

Omalizumab’s pharmacokinetics are linear at doses higher than 0.5 mg/kg. Following multiple doses, the area under the serum concentration-time curve (AUC) increases, reaching up to 6-fold higher at steady state compared to the first dose in asthma patients. The apparent volume of distribution in asthma patients is approximately 78 ± 32 mL/kg following subcutaneous administration. The drug is degraded in the reticuloendothelial system and endothelial cells, a common pathway for IgG antibodies. The serum elimination half-life averages around 26 days in asthma patients and 24 days in CSU patients at steady state. Clearance involves both IgG clearance mechanisms and specific binding and complex formation with its target ligand, IgE.

4.2. Pharmacodynamics

The primary pharmacodynamic effect of omalizumab is a dose-dependent reduction in free IgE levels in the serum. Within an hour of the first dose, free IgE levels are substantially reduced and remain suppressed between doses. For recommended doses in asthma, the mean serum free IgE decrease is typically greater than 96%, leading to free IgE concentrations well below 25 ng/mL on average.

Conversely, total serum IgE levels (which include IgE bound to omalizumab) paradoxically increase after the first dose due to the formation of omalizumab-IgE complexes, which have a slower elimination rate than free IgE. These complexes are biologically inert and do not activate effector cells. This rise in total IgE levels can be up to five-fold higher than pre-treatment levels by 16 weeks. Upon discontinuation of omalizumab, the decrease in free IgE is reversible, with no observed rebound in IgE levels. The reduction in free IgE also leads to the gradual downregulation of FcεRI receptors on immune cells, making them less sensitive to IgE-mediated stimulation. This multi-pronged pharmacodynamic action underpins its sustained therapeutic benefits.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

5. Safety Profile and Long-Term Data

Omalizumab is generally considered to have a favorable safety profile, with extensive data from clinical trials and real-world studies supporting its long-term use across various patient populations, including children.

5.1. Common Adverse Events

The most frequently reported adverse events (AEs) across indications are typically mild to moderate in severity. In asthma patients aged 12 years and older, common AEs include arthralgia (joint pain), general pain, leg pain, fatigue, dizziness, fracture, arm pain, pruritus, dermatitis, and earache. For pediatric asthma patients aged 6 to less than 12 years, nasopharyngitis, headache, pyrexia (fever), upper abdominal pain, pharyngitis, otitis media, viral gastroenteritis, arthropod bite, and epistaxis are commonly observed. In CRSwNP, common AEs include headache, injection site reaction, arthralgia, upper abdominal pain, and dizziness. For CSU patients, common AEs include headache, fatigue, flu-like symptoms, and mild joint pain. Injection site reactions (e.g., erythema, pain, swelling, pruritus) are also a common, albeit usually mild, occurrence across all indications.

5.2. Serious Adverse Events and Long-Term Safety Concerns

While generally well-tolerated, specific serious adverse events have been noted and extensively investigated. The most significant concern is anaphylaxis, which, though rare (0.1% in premarketing asthma trials), can be life-threatening. Anaphylaxis can occur after the first dose or even beyond one year of treatment, necessitating careful patient observation post-administration and patient education on recognizing symptoms.

Other safety concerns that have been raised and evaluated include:

• Malignancy: Cases of cancer have been observed in some patients receiving omalizumab. However, data from clinical trials and post-marketing surveillance have been extensively evaluated, and definitive causality has not been established. The risk of malignancy appears to be small and largely within the background population risk.
• Cardiovascular Events: Concerns regarding cardiovascular events have been raised, but comprehensive evaluations of clinical trial and real-world data have generally not shown a significant increase in risk directly attributable to omalizumab.
• Infections: While some studies have explored a potential link to infections, overall data suggest omalizumab does not significantly increase the risk of serious infections. Some specific infections, such as parasitic (worm) infections, have been noted in high-risk populations, warranting consideration.
• Autoimmune Diseases: While rare, some reports of serum sickness and other autoimmune manifestations have occurred, especially in pediatric patients, although causality is not always clear.

Long-term real-world effectiveness and safety studies provide reassuring data. For instance, a 16-year follow-up study on omalizumab in severe allergic asthma demonstrated significant and lasting improvements in exacerbations, asthma control, and lung function, alongside a reassuring safety profile with no systemic or local adverse effects, immunological pathologies, infections, or neoplasms detected over the prolonged treatment period. Similarly, long-term studies in pediatric asthma and CSU have confirmed its sustained efficacy and favorable safety, with low frequency and severity of adverse events. The ability to administer omalizumab even to pregnant women in some cases, highlighting its safety profile, further underscores its generally well-tolerated nature.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

6. Drug Interactions

Omalizumab, as a biological agent targeting IgE, generally exhibits a low propensity for direct drug-drug interactions via cytochrome P450 enzymes, which are commonly involved in the metabolism of many small-molecule drugs. This is because monoclonal antibodies are typically degraded via proteolytic pathways, rather than the cytochrome P450 system.

However, potential interactions should be considered in the context of its immunological mechanism. While some sources state no noted severe, serious, moderate, or minor interactions with other drugs, others suggest caution when combined with other monoclonal antibodies or immunosuppressants. For example, the risk or severity of adverse effects can be increased when omalizumab is combined with other biologics such as Brentuximab vedotin, Brodalumab, Brolucizumab, Burosumab, Canakinumab, Caplacizumab, Adalimumab, Dupilumab, and others. This is not necessarily a pharmacokinetic interaction but rather a potential for additive or synergistic immunomodulatory effects, which could theoretically increase the risk of infections or other immune-related adverse events. Patients typically receive omalizumab as an add-on therapy to existing standard-of-care treatments, such as inhaled corticosteroids for asthma or H1-antihistamines for CSU, without significant contraindications for co-administration. Therefore, while direct pharmacological interactions are minimal, clinicians should be mindful of the overall immunological impact when combining omalizumab with other immunomodulatory agents.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

7. Cost-Benefit Analysis

Omalizumab represents a significant advancement in the treatment of severe allergic and inflammatory conditions, but its high acquisition cost is a notable consideration in healthcare economics. A thorough cost-benefit analysis involves weighing these costs against the substantial clinical benefits and reductions in healthcare resource utilization.

7.1. Costs

Omalizumab is an expensive medication, and its price can vary significantly depending on the region, dosage, and frequency of administration. For asthma, dosing is determined by body weight and IgE levels, leading to varied costs per patient. For CSU, a fixed dose is typically used. The cumulative cost over long-term treatment periods can be substantial, leading to challenges in healthcare budgeting and access for some patients.

7.2. Benefits and Cost-Effectiveness

Despite the high upfront cost, the clinical benefits of omalizumab translate into significant long-term economic advantages. For patients with severe allergic asthma, omalizumab leads to:

• Reduced Exacerbations and Hospitalizations: By effectively controlling asthma, omalizumab dramatically reduces the frequency of severe exacerbations, emergency room visits, and hospitalizations, which are major drivers of healthcare costs. Hospital admissions for asthma are particularly costly, and preventing them can offset a substantial portion of the drug’s price.
• Decreased Oral Corticosteroid (OCS) Use: Omalizumab’s OCS-sparing effect is a critical benefit. Long-term OCS use is associated with numerous severe adverse effects (e.g., osteoporosis, diabetes, hypertension, cataracts), leading to additional medical costs and significantly impacting patient quality of life. Reducing or eliminating OCS can lead to substantial savings in managing these comorbidities.
• Improved Productivity and Quality of Life: Effective disease control translates into improved quality of life, fewer days missed from work or school, and enhanced productivity for patients and caregivers. While difficult to quantify precisely, these societal benefits contribute to the overall cost-effectiveness.

Similarly, in CSU, omalizumab significantly improves quality of life and reduces the need for frequent healthcare visits associated with uncontrolled hives and angioedema. In CRSwNP, it reduces the need for systemic corticosteroids and revision surgeries, which also carry significant costs and morbidity. For food allergy, reducing the risk of anaphylaxis, a life-threatening event requiring emergency medical intervention, offers invaluable benefit, though the direct economic savings might be harder to quantify given the prophylactic nature of the treatment. However, preventing even a single anaphylactic episode can avert considerable emergency care costs and potential long-term complications.

Overall, various pharmacoeconomic evaluations have shown that despite its high price, omalizumab can be cost-effective in specific patient populations, particularly those with severe disease who are poorly controlled by conventional therapies. The decision to prescribe omalizumab often involves a careful consideration of the patient’s disease severity, response to previous treatments, and the potential for healthcare resource savings and quality of life improvements. From a societal perspective, the ability to control debilitating chronic conditions and prevent acute, costly events makes a compelling argument for its value.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

8. Future Perspectives and Emerging Indications

The success of omalizumab in its approved indications has naturally led to exploration of its potential in other IgE- or mast cell-driven diseases. The understanding that omalizumab acts not only by neutralizing IgE but also by modulating mast cell and basophil function opens avenues for broader application.

While currently approved indications are well-established, research continues to evaluate omalizumab in other allergic and inflammatory conditions. For instance, its role in atopic dermatitis (AD) has been explored, given the often elevated IgE levels and mast cell involvement in severe AD. Some studies suggest potential for symptom improvement, particularly in pediatric AD, though current indications are limited. Similarly, there is ongoing research into its use in seasonal allergic rhinitis (SAR) and other forms of chronic urticaria beyond CSU, such as chronic inducible urticaria. The expanding understanding of IgE’s role beyond classical allergy, including its influence on various inflammatory pathways, could further broaden omalizumab’s therapeutic landscape.

Furthermore, optimizing dosing strategies, identifying biomarkers for predicting treatment response, and understanding the optimal duration of therapy remain active areas of investigation. The development of biosimilar versions of omalizumab, such as Omalizumab-igec and Omlyclo, also holds promise for potentially reducing treatment costs and improving accessibility in the future, thereby expanding its reach to more patients who could benefit from this transformative therapy. The integration of real-world evidence into clinical guidelines will continue to refine its appropriate use and expand its evidence base.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

9. Conclusion

Omalizumab has firmly established itself as a cornerstone therapy for several severe allergic and inflammatory conditions, profoundly impacting the lives of patients with moderate-to-severe allergic asthma, chronic spontaneous urticaria, chronic rhinosinusitis with nasal polyps, and IgE-mediated food allergy. Its precise mechanism of action, involving the sequestration of free IgE and the subsequent downregulation of IgE receptors on effector cells, effectively dampens allergic and inflammatory cascades.

The robust evidence from numerous clinical trials and a growing body of real-world studies consistently demonstrates its high efficacy in reducing disease exacerbations, improving symptom control, enhancing lung function, and significantly improving quality of life across diverse patient populations, including children and adolescents. Notably, in pediatric chronic spontaneous urticaria, where treatment options are often limited, omalizumab offers substantial symptomatic relief with an acceptable safety profile.

While the drug carries a high acquisition cost, a comprehensive cost-benefit analysis reveals that its clinical advantages, such as reduced hospitalizations, decreased reliance on systemic corticosteroids, and improved productivity, often translate into significant healthcare savings and societal benefits that can offset the initial investment. The long-term safety data are largely reassuring, with serious adverse events being rare and manageable. As research progresses, the therapeutic spectrum of omalizumab may further expand, and the advent of biosimilars may enhance its accessibility. Omalizumab represents a critical therapeutic innovation that continues to redefine the management of challenging IgE-mediated diseases, underscoring the profound impact of targeted biological therapies in modern medicine.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

10. References

Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria – PMC. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6647413/ (Accessed June 29, 2025).
Omalizumab: Uses, Interactions, Mechanism of Action | DrugBank Online. https://go.drugbank.com/drugs/DB00043 (Accessed June 29, 2025).
Omalizumab in pediatric chronic spontaneous urticaria: A systematic review and meta-analysis of efficacy and safety – PubMed. https://pubmed.ncbi.nlm.nih.gov/37299092/ (Accessed June 29, 2025).
Omalizumab treatment in adolescents with chronic spontaneous urticaria: Efficacy and safety | Allergologia et Immunopathologia – Elsevier. https://www.sciencedirect.com/science/article/pii/S030105461930061X (Accessed June 29, 2025).
Omalizumab – Wikipedia. https://en.wikipedia.org/wiki/Omalizumab (Accessed June 29, 2025).
Efficacy and Safety of Omalizumab Treatment Over a 16-Year Follow-Up: When a Clinical Trial Meets Real-Life. https://www.mdpi.com/2077-0383/11/9/2405 (Accessed June 29, 2025).
Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria – PubMed. https://pubmed.ncbi.nlm.nih.gov/37190013/ (Accessed June 29, 2025).
XOLAIR® (omalizumab): Allergic Asthma, CSU, CRSwNP & Food Allergy. https://www.xolair.com/ (Accessed June 29, 2025).
Pharmacokinetics, pharmacodynamics and clinical efficacy of omalizumab for the treatment of asthma – Taylor & Francis Online: Peer-reviewed Journals. https://www.tandfonline.com/doi/full/10.1517/14740338.2016.1158102 (Accessed June 29, 2025).
Efficacy and safety of omalizumab in chronic rhinosinusitis with nasal polyps: a systematic review and meta-analysis of randomised controlled trials | BMJ Open. https://bmjopen.bmj.com/content/11/9/e047344 (Accessed June 29, 2025).
A Clinical Trial of Omalizumab in Participants With Chronic Rhinosinusitis With Nasal Polyps. https://clinicaltrials.gov/study/NCT03280524 (Accessed June 29, 2025).
Efficacy and safety of omalizumab in patients with moderate-to-severe asthma: An analytic comparison of data from randomized con. https://www.jthoracdis.com/article/view/17812/html (Accessed June 29, 2025).
Mechanism of action of omalizumab. Omalizumab binds to IgE, thus… – ResearchGate. https://www.researchgate.net/figure/Mechanism-of-action-of-omalizumab-Omalizumab-binds-to-IgE-thus-forming-immune_fig1_323497525 (Accessed June 29, 2025).
Omalizumab: Side Effects, Uses, Dosage, Interactions, Warnings – RxList. https://www.rxlist.com/omalizumab/side-effects-drug-center.htm (Accessed June 29, 2025).
Long-term efficacy and safety of omalizumab for nasal polyposis in an open-label extension study. https://www.jacionline.org/article/S0091-6749(21)01463-X/fulltext (Accessed June 29, 2025).
Omalizumab Interactions Checker – Drugs.com. https://www.drugs.com/drug-interactions/omalizumab.html (Accessed June 29, 2025).
Side Effects & Safety Profile | XOLAIR® (omalizumab). https://www.xolair.com/safety-side-effects/crsw_np.html (Accessed June 29, 2025).
Side Effects & Safety Profile | XOLAIR® (omalizumab). https://www.xolair.com/safety-side-effects/asthma.html (Accessed June 29, 2025).
Xolair, Omlyclo (omalizumab) dosing, indications, interactions, adverse effects, and more – Medscape Drugs. https://reference.medscape.com/drug/xolair-omlyclo-omalizumab-999014 (Accessed June 29, 2025).
Omalizumab – StatPearls – NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK535384/ (Accessed June 29, 2025).
XOLAIR® (omalizumab) for injection, for subcutaneous use – accessdata.fda.gov. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103976s5232lbl.pdf (Accessed June 29, 2025).
Efficacy and Safety of Omalizumab for the Treatment of Severe or Poorly Controlled Allergic Diseases in Children: A Systematic Review and Meta-Analysis – Frontiers. https://www.frontiersin.org/articles/10.3389/fped.2022.868735/full (Accessed June 29, 2025).
Efficacy and Safety of Omalizumab and Dupilumab in Pediatric Patients with Skin Diseases: An Observational Study – MDPI. https://www.mdpi.com/2077-0383/12/13/4491 (Accessed June 29, 2025).
Safety and effectiveness of omalizumab for the treatment of chronic urticaria in pediatric patients – PMC. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8900600/ (Accessed June 29, 2025).
Efficacy and safety of omalizumab in chronic rhinosinusitis with nasal polyps: a systematic review and meta-analysis of randomised controlled trials – PubMed. https://pubmed.ncbi.nlm.nih.gov/34480036/ (Accessed June 29, 2025).
Pharmacokinetics, pharmacodynamics and clinical efficacy of omalizumab for the treatment of asthma – PubMed. https://pubmed.ncbi.nlm.nih.gov/26999266/ (Accessed June 29, 2025).
Long-term efficacy and safety of omalizumab in patients with allergic asthma: A real-life study – PubMed. https://pubmed.ncbi.nlm.nih.gov/33980337/ (Accessed June 29, 2025).
Relationship between omalizumab pharmacokinetics, IgE pharmacodynamics and symptoms in patients with severe persistent allergic (IgE-mediated) asthma – PubMed Central. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2783050/ (Accessed June 29, 2025).
Omalizumab safety concerns – PubMed. https://pubmed.ncbi.nlm.nih.gov/38318685/ (Accessed June 29, 2025).
Meta-Analysis Examines Omalizumab for Urticaria in Children – Medscape. https://www.medscape.com/viewarticle/999818 (Accessed June 29, 2025).
Efficacy and safety of omalizumab in children with moderate-to-severe asthma: a meta-analysis – Taylor & Francis Online: Peer-reviewed Journals. https://www.tandfonline.com/doi/full/10.1080/07853890.2017.1352485 (Accessed June 29, 2025).
Omalizumab. A review of the new treatment of allergic asthma and seasonal allergic rhinitis | Allergologia et Immunopathologia – Elsevier. https://www.sciencedirect.com/science/article/abs/pii/S0301054602700344 (Accessed June 29, 2025).
A mechanism-based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab – researchmap. https://researchmap.jp/read0016629_published_papers/content_type/journals/id/4006240/attachment/0 (Accessed June 29, 2025).
Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials – PubMed. https://pubmed.ncbi.nlm.nih.gov/32497672/ (Accessed June 29, 2025).
Xolair Interactions Checker – Drugs.com. https://www.drugs.com/drug-interactions/xolair.html (Accessed June 29, 2025).
Important Safety Information – XOLAIR® (omalizumab) Side Effects. https://www.xolair.com/safety-side-effects.html (Accessed June 29, 2025).
Long-Term Safety of Omalizumab in Children with Asthma and/or Chronic Spontaneous Urticaria: A 4-Year Prospective Study in Real Life – MDPI. https://www.mdpi.com/2077-0383/12/13/4224 (Accessed June 29, 2025).
Long-term efficacy and safety of omalizumab in patients with allergic asthma: A real-life study | Request PDF – ResearchGate. https://www.researchgate.net/publication/351656897_Long-term_efficacy_and_safety_of_omalizumab_in_patients_with_allergic_asthma_A_real-life_study (Accessed June 29, 2025).
Xolair Interactions: Other Medications, Alcohol, and More – Healthline. https://www.healthline.com/health/xolair-interactions (Accessed June 29, 2025).
Real-life Effectiveness of Omalizumab in Patients with Severe Allergic Asthma: RELIEF Study – The Open Respiratory Medicine Journal. https://openresmedj.com/VOLUME/16/PAGE/e187430632207220/FULLTEXT/ (Accessed June 29, 2025).
Short- and long-term real-world effectiveness of omalizumab in severe allergic asthma – Research Bank. https://researchbank.swinburne.edu.au/file/98482436-e41c-4340-97ce-88c9f56059d6/1/PDF%20(1).pdf (Accessed June 29, 2025).
Real-life efficacy and safety of omalizumab in Portuguese patients with persistent uncontrolled asthma | Pulmonology. https://www.pulmonology.gr/article/real-life-efficacy-and-safety-omalizumab-portuguese-patients-persistent-uncontrolled-asthma (Accessed June 29, 2025).
Long-term effectiveness and safety of omalizumab in pediatric and adult patients with moderate-to-severe inadequately controlled allergic asthma – PubMed. https://pubmed.ncbi.nlm.nih.gov/36181712/ (Accessed June 29, 2025).